CTOs on the Move

Kindeva Drug Delivery

www.kindevadd.com

 
Kindeva is a global force in combination drug delivery and manufacturing. Leveraging more than 100 years of innovation, Kindeva provides unrivaled expertise at every stage of pulmonary & nasal, injectable, and transdermal therapy development and manufacturing. Whether determining ideal delivery and dosage or scaling sterile manufacturing and fill-finish operations, every solution is backed by extensive technological capabilities, deep regulatory knowledge, and nine state-of-the-art facilities. Kindeva`s proactive, informed solutions minimize risk and maximize confidence from ideation through commercialization, bringing high-quality products to patients in need, faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Shanmugasundaram Sathish
VP, Digital and Enterprise Applications Profile
Marjorie Nehring
Associate Director of Information Technology - Quality and Manufacturing Applications Profile

Similar Companies

Vishay BLH

BLH provides precision load cells, weight and force measurement systems, strain gages, web tension transducers, and instrumentation

REM Associates

REM Associates is a Bonsall, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Equipment Doctor

At Medical Equipment Doctor we partner up with you to keep your budget and costs in check by providing pre-owned medical equipment sales, serviceand rental for all your facility needs. Contact us today.

Horizon Therapeutics

At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.